Agreement is for manufacturing scale up of Leonardo's nanoparticles
Story content courtesy of Arrowhead Research Corporation, US
The two emerging drug delivery companies signed a development contract in which NanoMedical Systems (NMS) will develop and establish a commercial process to manufacture nanoporous silicon particles for Leonardo's multi-stage drug delivery system, preparing their manufacturing particles to be suitable for clinical trials. "Our medical device engineering quality system is designed to produce an FDA-compliant process that will bring Leonardo to the doorstep of clinical testing of their innovative drug delivery products,” notes Randy Goodall, President and CEO of NanoMedical Systems.
TechConnect News Note: NanoMedical Systems was selected to present at TechConnect Ventures 2011, Boston, MA. To view the company’s profile, visit: http://www.techconnectworld.com/Summit2011/a.html?i=40297.
